Jurczyńska Jolanta, Stepień Tomasz, Lawnicka Hanna, Stepień Henryk, Krupiński Ryszard, Kołomecki Krzysztof, Kuzdak Krzysztof, Komorowski Jan
Department of Clinical Endocrinology, Medical University, Łódź.
Endokrynol Pol. 2009 Jan-Feb;60(1):9-13.
Neoangiogenesis appears to be an important event in tumour invasion and in the formation of metastases in many endocrine-related human cancers. Vascular endothelial growth factor (VEGF) is a glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells and acts through VEGF receptors. The aim of the study was to evaluate the plasma blood concentrations of VEGF, sVEGFR1, and sVEGFR2 in patients with benign and malignant adrenal tumours treated by surgery.
We studied the blood before surgery of 41 patients with adrenal cortex tumours and 10 normal subjects without hormonal or CT/USG pathology of the adrenal glands (controls). We studied the blood after adrenalectomy of 16 patients with tumours of the adrenal cortex.
Concentrations of VEGF, sVEGFR1 and sVEGFR2 in blood plasma before as well as 30 days after surgery were evaluated by ELISA. VEGF blood concentrations before surgery did not differ in the patients with the cortical tumours as compared to the controls. After surgery VEGF concentrations decreased among the patients, taken in total, with adrenal cortex tumours and cortical adenomas. Before surgery sVEGFR1 blood concentrations were increased in the patients with Conn's syndrome only in comparison with the controls. After surgery, sVEGFR1 concentrations decreased significantly in the group with cortical adenomas only. Before and after surgery sVEGFR2 blood concentrations did not differ between the groups of patients studied and the controls.
Peripheral blood concentrations of VEGF and its receptors cannot be clinically valuable markers that discriminate between benign and malignant adrenocortical tumours before and after adrenalectomy.
在许多内分泌相关的人类癌症中，新生血管生成似乎是肿瘤侵袭和转移形成过程中的一个重要事件。血管内皮生长因子（VEGF）是一种糖蛋白，具有对内皮细胞特异的强大血管生成、促有丝分裂和增强血管通透性的活性，并通过VEGF受体发挥作用。本研究的目的是评估接受手术治疗的良性和恶性肾上腺肿瘤患者血浆中VEGF、可溶性VEGF受体1（sVEGFR1）和可溶性VEGF受体2（sVEGFR2）的浓度。
我们研究了41例肾上腺皮质肿瘤患者术前的血液以及10例无肾上腺激素或CT/USG病变的正常受试者（对照组）的血液。我们还研究了16例肾上腺皮质肿瘤患者肾上腺切除术后的血液。
通过酶联免疫吸附测定法（ELISA）评估了手术前以及术后30天血浆中VEGF、sVEGFR1和sVEGFR2的浓度。与对照组相比，皮质肿瘤患者术前的VEGF血液浓度无差异。总体而言，肾上腺皮质肿瘤和皮质腺瘤患者术后VEGF浓度降低。术前，仅原发性醛固酮增多症患者的sVEGFR1血液浓度与对照组相比有所升高。术后，仅皮质腺瘤组的sVEGFR1浓度显著降低。术前和术后，所研究的患者组与对照组之间的sVEGFR2血液浓度无差异。
VEGF及其受体的外周血浓度在肾上腺切除术前和术后均不能作为区分良性和恶性肾上腺皮质肿瘤的有临床价值的标志物。
